Literature DB >> 15240671

Differential roles for CCR5 expression on donor T cells during graft-versus-host disease based on pretransplant conditioning.

Christian A Wysocki1, Susan B Burkett, Angela Panoskaltsis-Mortari, Suzanne L Kirby, Andrew D Luster, Karen McKinnon, Bruce R Blazar, Jonathan S Serody.   

Abstract

The coordinated expression of chemokines and receptors may be important in the directed migration of alloreactive T cells during graft-vs-host disease (GVHD). Recent work demonstrated in a murine model that transfer of CCR5-deficient (CCR5(-/-)) donor cells to nonconditioned haploidentical recipients resulted in reduced donor cell infiltration in liver and lymphoid tissues compared with transfer of CCR5(+/+) cells. To investigate the function of CCR5 during GVHD in conditioned transplant recipients, we transferred CCR5(-/-) or wild-type C57BL/6 (B6) T cells to lethally irradiated B6D2 recipients. Unexpectedly, we found an earlier time to onset and a worsening of GVHD using CCR5(-/-) T cells, which was associated with significant increases in the accumulation of alloreactive CD4(+) and CD8(+) T cells in liver and lung. Conversely, the transfer of CCR5(-/-) donor cells to nonirradiated recipients led to reduced infiltration of target organs, confirming previous studies and demonstrating that the role of CCR5 on donor T cells is dependent on conditioning of recipients. Expression of proinflammatory chemokines in target tissues was dependent on conditioning of recipients, such that CXCL10 and CXCL11 were most highly expressed in tissues of irradiated recipients during the first week post-transplant. CCR5(-/-) T cells were shown to have enhanced migration to CXCL10, and blocking this ligand in vivo improved survival in irradiated recipients receiving CCR5(-/-) T cells. Our data indicate that the effects of inhibiting CCR5/ligand interaction on donor T cells during GVHD differ depending on conditioning of recipients, a finding with potentially important clinical significance.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15240671     DOI: 10.4049/jimmunol.173.2.845

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  53 in total

1.  Attenuation of acute graft-versus-host disease in the absence of the transcription factor RORγt.

Authors:  LeShara M Fulton; Michael J Carlson; James M Coghill; Laura E Ott; Michelle L West; Angela Panoskaltsis-Mortari; Dan R Littman; Bruce R Blazar; Jonathan S Serody
Journal:  J Immunol       Date:  2012-07-09       Impact factor: 5.422

2.  Apoptotic neutrophils and T cells sequester chemokines during immune response resolution through modulation of CCR5 expression.

Authors:  Amiram Ariel; Gabrielle Fredman; Yee-Ping Sun; Alpdogan Kantarci; Thomas E Van Dyke; Andrew D Luster; Charles N Serhan
Journal:  Nat Immunol       Date:  2006-10-01       Impact factor: 25.606

Review 3.  Human and murine obliterative bronchiolitis in transplant.

Authors:  John F McDyer
Journal:  Proc Am Thorac Soc       Date:  2007-01

4.  Villitis of unknown etiology is associated with a distinct pattern of chemokine up-regulation in the feto-maternal and placental compartments: implications for conjoint maternal allograft rejection and maternal anti-fetal graft-versus-host disease.

Authors:  Mi Jeong Kim; Roberto Romero; Chong Jai Kim; Adi L Tarca; Sovantha Chhauy; Christopher LaJeunesse; Deug-Chan Lee; Sorin Draghici; Francesca Gotsch; Juan Pedro Kusanovic; Sonia S Hassan; Jung-Sun Kim
Journal:  J Immunol       Date:  2009-03-15       Impact factor: 5.422

Review 5.  An official American Thoracic Society research statement: noninfectious lung injury after hematopoietic stem cell transplantation: idiopathic pneumonia syndrome.

Authors:  Angela Panoskaltsis-Mortari; Matthias Griese; David K Madtes; John A Belperio; Imad Y Haddad; Rodney J Folz; Kenneth R Cooke
Journal:  Am J Respir Crit Care Med       Date:  2011-05-01       Impact factor: 21.405

6.  L-selectin and beta7 integrin on donor CD4 T cells are required for the early migration to host mesenteric lymph nodes and acute colitis of graft-versus-host disease.

Authors:  Suparna Dutt; Joerg Ermann; Diane Tseng; Yin Ping Liu; Tracy I George; C Garrison Fathman; Samuel Strober
Journal:  Blood       Date:  2005-08-16       Impact factor: 22.113

7.  In vitro-differentiated TH17 cells mediate lethal acute graft-versus-host disease with severe cutaneous and pulmonary pathologic manifestations.

Authors:  Michael J Carlson; Michelle L West; James M Coghill; Angela Panoskaltsis-Mortari; Bruce R Blazar; Jonathan S Serody
Journal:  Blood       Date:  2008-10-28       Impact factor: 22.113

Review 8.  Next generation treatment of acute graft-versus-host disease.

Authors:  J Magenau; P Reddy
Journal:  Leukemia       Date:  2014-06-18       Impact factor: 11.528

9.  Reciprocal differentiation and tissue-specific pathogenesis of Th1, Th2, and Th17 cells in graft-versus-host disease.

Authors:  Tangsheng Yi; Ying Chen; Lin Wang; Gong Du; Daniel Huang; Dongchang Zhao; Heather Johnston; James Young; Ivan Todorov; Dale T Umetsu; Lieping Chen; Yoichiro Iwakura; Fouad Kandeel; Stephen Forman; Defu Zeng
Journal:  Blood       Date:  2009-07-14       Impact factor: 22.113

10.  Proteomics analysis reveals a Th17-prone cell population in presymptomatic graft-versus-host disease.

Authors:  Wei Li; Liangyi Liu; Aurelie Gomez; Jilu Zhang; Abdulraouf Ramadan; Qing Zhang; Sung W Choi; Peng Zhang; Joel K Greenson; Chen Liu; Di Jiang; Elizabeth Virts; Stephanie L Kelich; Hong Wei Chu; Ryan Flynn; Bruce R Blazar; Helmut Hanenberg; Samir Hanash; Sophie Paczesny
Journal:  JCI Insight       Date:  2016-05-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.